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Abstract
Background: Aberrant expression of the RON receptor tyrosine kinase, a member of the MET proto-oncogene
family, in breast cancer and non-small cell lung cancer (NSCLC) has therapeutic implication. Here we evaluated the
efficacy of a novel anti-RON antibody-drug maytansinoid conjugate Zt/g4-DM1 for treatment of breast and NSCLC
xenograft tumors in mouse models and explored a treatment strategy by combination of Zt/g4-DM1 with
chemotherapeutics to achieve the maximal therapeutic activity.
Methods: Mouse monoclonal antibody Zt/g4 (IgG1a/κ) specific to human RON was conjugated to DM1 via
thioether linkage to form Zt/g4-DM1 with a drug-antibody ratio of 4:1. Several breast cancer and NSCLC cell lines,
expressing different levels of RON, were used as the model. Immunofluorescence was used to determine Zt/g4-
induced RON internalization. Flow cytometric analysis and cell viability assay were used to determine the effect of
Zt-g4-DM1 on cell cycle and death. Mouse xenograft NSCLC models were used in vivo to determine the
therapeutic efficacy of Zt/g4-DM1 alone or in combination with chemotherapeutics.
Results: In vitro, Zt/g4 treatment of breast cancer and NSCLC cells rapidly induced cell surface RON internalization,
which results in intracellular delivery of DM1 sufficient to arrest cell cycle at G2/M phase, reduce cell viability, and
cause massive cell death. In mouse tumor xenograft models, Zt/g4-DM1 at 20 mg/kg in a Q12 × 2 regimen
effectively blocked breast cancer and NSCLC cell- mediated tumor growth. More than 95 % inhibition of tumor
growth among three tumor xenograft models tested was achieved according to the measured tumor volume. The
minimal dose to balance the tumor growth and inhibition (tumoristatic concentration) was established at 2.02
mg/kg for H2228, 1.94 mg/kg for H358 cell, and 6.25 mg/kg for T-47D cell-mediated xenograft tumors.
Conclusion: Zt/g4 is highly effective in RON-directed drug delivery for targeted inhibition of NSCLC cell-derived
tumor growth in mouse xenograft models. This work provides the basis for clinical development of humanized
Zt/g4-DM1 for potential cancer therapy in the future.
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Background
Antibody-directed drug delivery in the form of antibody-
drug conjugates (ADC) is a promising anti-cancer strategy
[1–3]. Structurally, ADC is formed by a target-specific
monoclonal antibody (mAb) conjugated with a highly
potent toxic drug through a versatile linker at a pre-
cise drug- antibody ratio [1–3]. Since 2012, two
ADCs, ado-trastuzumab emtansine (T-DM1, Kadcyla,
Roche-Genentech) and brentuximab vedotin (SGN-35,
Adcetris, Seattle Genetics) have been approved for
targeted therapy of breast cancer (BC) and lymph-
omas, respectively [4–7]. T-DM1 is specific to HER2
expressed by BC [4]. SGN-35 targets the CD30 anti-
gen, a cell surface antigen expressed by Hodgkin’s
and other subsets of lymphoma cells [6, 7]. Currently,
ADCs employing different antibodies targeting different
cell surface proteins such as PSMA [8, 9]. Ephrin-A4 [10],
CD78B [11, 12], Trop-2 [13], and LY6E [14] are under in-
tensive study in preclinical models. More than 30 ADCs
are under clinical trials (www.clinicaltrials.gov). Thus,
ADCs represent a promising therapeutic modality for the
clinical management of cancer.
The RON receptor tyrosine kinase is a member of the
MET proto-oncogene family implicated in the pathogenesis
of BC and non-small cell lung cancer (NSCLC) [15–20].
Immunohistochemical staining using specific antibodies
has shown increased RON expression in primary BC and
NSCLC samples [21–24], which results in aberrant signal-
ing facilitating cancerous cell growth, migration, and inva-
sion [16]. Overexpression of RON also has been considered
as a potential drug target for cancer treatment [25–29].
Currently, RON-specific therapeutics including tyrosine
kinase inhibitors (TKI) and therapeutic monoclonal
antibodies (TMA) have been developed and validated
in various preclinical cancer models [25–29]. Clinical
trials using RON-specific TKIs and TMAs are also
under investigation (www.clinicaltrials.gov). Evidence
accumulated from various studies showed that inhibition
of RON has the therapeutic effects on cancer cell growth,
migration, and survival [25–29]. However, the efficacy of
RON- specific TKIs and TMAs is relatively low with only
partial tumor inhibition [25–29]. The inability of anti-
RON TKIs and TMAs to achieve the maximal effect is
mainly due to the lack of complete addiction of cancer
cells to RON signaling for growth and survival [16]. Thus,
it is critical to improve the drug efficacy for the success of
RON-targeted cancer therapy.
For the last several years, we have focused on anti-
RON mAb-directed drug delivery for targeted cancer
therapy [25, 30–32]. Several mAbs specific to human
RON were produced and selected for their suitability for
RON-targeted drug delivery [25, 30–32]. Zt/g4 is one of
the anti- RON mAbs chosen for RON-targeted drug de-
livery [25, 33, 34]. Zt/g4 recognizes an antigenic epitope
located in the Sema domain of the RON extracellular se-
quence and induces rapid internalization of the cell sur-
face RON molecules [25, 33, 34]. This property makes
Zt/g4 a suitable candidate to conjugate with DM1 to
form anti-RON ADC Zt/g4-DM1 for targeted drug de-
livery. In this study, we used BC and NSCLC cells as the
experimental models to determine the effectiveness of
Zt/g4 in induction of RON internalization by a panel of
BC and NSCLC cell lines expressing different levels of
RON. The cytotoxic activity of anti-RON ADC Zt/g4-
DM1 was evaluated in both in vitro cell lines and in vivo
xenograft tumor models. Moreover, we explored a treat-
ment strategy by combination of Zt/g4-DM1 with che-
motherapeutics to achieve the maximal therapeutic
activity against BC and NSCLC xenograft tumors. We
believe that results from these studies confirm the po-
tentials of anti-RON ADC for BC and NSCLC treatment
and establish the foundation for development of human-
ized anti-RON ADC.
Methods
Cell lines and reagents
Human BC cell lines MCF-7, DU4475, MDA-MB-231,
T-47D, and NSCLC cell lines H1993, H2228, and H358
were from ATCC (Manassas, VA). Mouse anti-RON
mAbs Zt/g4, Zt/c1 and rabbit anti-RON IgG antibodies
were as previously described [33]. Goat anti-mouse IgG
labeled with FITC or rhodamine was from Jackson
ImmunoResearch (West Grove, PA).
Generation of Zt/g4-DM1
Zt/g4 was conjugated with DM1 at a drug-antibody ratio
of 4:1 by through the linker SMCC as previously de-
scribed [1, 4, 25, 35]. Control mouse IgG conjugated
with DM1 (CmIgG-DM1) was used as the control. The
Zt/g4-DM1 was verified by HIC using a Varian Prostar
210 Quaternary HPLC system coupled with a TSK
butyl-NPR 4.6 × 3,5 column (Tosoh Biosciences (Prussia,
PA) [25].
Assay for cell surface RON expression
Cell surface RON was quantitatively determined by the
immunofluorescence assay using QIFKIT® reagents from
DAKO (Carpentaria, CA). Briefly, cells (1 × 106 cells per
ml in PBS) were treated with Zt/g4 at saturating concen-
trations followed by incubation in parallel with the QIFI-
KIT® beads and goat F(ab’)2 F0479. After establishing a
calibration curve, the number of RON receptor on the
cell surface was determined by interpolation following
the manufacturer’s instruction.
Analysis of cell cycle
BC and NSCLC cells (1 × 106 cells per dish) were treated
with 5 μg/ml of Zt/g4-DM1 at 37 °C for 24 h. Cells were
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then labeled with propidium iodide followed by Accuri
flow cytometric analysis. Cell cycle changes were deter-
mined by measuring DNA contents as previously de-
scribed [36].
Western blot analysis
Cellular proteins (50 μg per sample) were separated in
an 8 % SDS- PAGE under reduced conditions. Cellular
proteins such as PARP were detected in Western blot-
ting using specific antibodies. Membranes also were
reprobed with anti-actin antibody to ensure equal sam-
ple loading [31].
Detection of intracellular RON
BC and NSCLC cells at 1 × 105 cells per well in a 6-well
plate were treated with 5 μg/ml of Zt/g4-DM1 for vari-
ous times followed by goat anti-mouse IgG coupled with
FITC [35]. Nuclear DNAs were stained with 4′,6-diami-
dino-2-phenylindole (DAPI) [36]. Cellular immunofluor-
escence was observed under an Olympus microscope
equipped with DUS/fluorescent apparatus.
Assays for cell viability and cell death
Cell viability 96 h after Zt/g4-DM1 treatment was deter-
mined by the MTT assay [31, 36]. Percentages of viable
or dead cells were determined using the trypan blue ex-
clusion assay as previously described [31, 36].
Mouse xenograft tumor model and anti-RON ADC
treatment
All experiments on mice were approved by the TTUHSC
Institutional Animal Care Committee. Female athymic
nude mice at 6 weeks of age (Taconic, Cranbury, NJ) were
injected with 5 × 106 cancer cells in the subcutaneous
space of the right flank as previously described [25, 33].
Mice were randomized into different groups (five mice
per group). Treatment began when tumors reaches a
mean tumor volume of ~100 mm3. To evaluate the Zt/g4-
DM1 efficacy, mice were injected with Zt/g4- DM1 at
20 mg/kg in a Q12 × 2 regimen. Tumor growth was ob-
served up to 52 days. In study of Zt/g4-DM1 in combin-
ation with gemcitabine, tumor-bearing mice were treated
with gemcitabine alone at 60 mg/kg in a Q4 × 4 schedule
[37], Zt/g4-DM1 alone at 10 mg/kg in a Q8 × 2 schedule,
or their combinations with above described concentra-
tions. Tumor volumes were measured every 4 days and
calculated as previously described [24, 25]. Animals were
euthanized when tumor volumes exceeded 2000 mm3 or
if tumors became necrotic or ulcerated through the skin.
Statistical analysis
GraphPad 6 software was used for statistical analysis. Re-
sults are shown as mean ± SD. The data between control
and experimental groups were compared using Student t
test. Chi-squared analysis was used for correlational
study. Isobolograms were used for analysis of synergism
in drug combination studies. Statistical differences at
p <0.05 were considered significant.
Results
Induction by Zt/g4-DM1 of cell surface RON
internalization
To study the effect of Zt/g4 on RON internalization, we
first determined the number of RON molecules expressed
on cell surface using the QIFKIT® fluorescence-based
quantitative method (Fig. 1a). The calculated RON mole-
cules on the surface of a single cell was 14,841 ± 266 for
DU4475, 8185 ± 256 for MDA-MB231, 15,756 ± 314 for
T-47D, 2152 ± 208 for H1993, 10,207 ± 278 for H2228,
and 15,286 ± 366 for H358 cells, respectively. Specific
binding was not observed in MCF-7 cells. The binding
profiles of DM1-conjugated Zt/g4 were shown in Fig. 1b.
Mouse IgG and its DM1 conjugates (CmIgG-DM1) were
used as the control. When antibodies were used at 5 μg
IgG per ml, the RON binding profile of Zt/g4-DM1 was
similar to that of free Zt/g4 among seven cell lines tested,
suggesting that DM1 conjugation does not impair the
binding capability of Zt/g4.
The effect of Zt/g4-DM1 on RON internalization is
shown in Fig. 1c. Zt/g4-DM1 treatment caused a pro-
gressive reduction of cell surface RON in a time-
dependent manner in all six cell lines tested. Less than
20 % of RON remained on the cell surface after a 36 h
treatment. The effect of Zt/g4-DM1 on RON expressed
by MCF-7 cells was minimal. We defined the time re-
quired to have a 50 % reduction in cell surface RON as
the internalization efficacy (IE50). The calculated IE50
values were >100 h for MCF-7, 14.32 h for DU4475,
11.71 h for MDA- MB-231, 23.46 h for T-47D, 11.65 h
for H1993, 7.47 h for H358, and 9.84 h for H2228 cells
(Fig. 1c). These results indicate that Zt/g4-DM1 differen-
tially induces RON internalization in different cancer
cells. Immunofluorescence analysis confirmed Zt/g4-
DM1-induced RON internalization in four selected cell
lines (Fig. 1d and e). RON was detected on the cell surface
at 4 °C. The internalization occurred at 37 °C after Zt/g4-
DM1 treatment. Cytoplasmic RON was co-localized with
LAMP1 in both BC and NSCLC cells. Thus, results from
Fig. 1 demonstrate that Zt/g4-DM1 effectively induces
RON internalization by BC and NSCLC cells.
Effect of Zt/g4-DM1 on cell cycle, growth, and death of
BC and NSCLC cells
The effect of Zt/g4-directed DM1 delivery on cell cycle
was shown in Fig. 2a. The changes in cell cycle were ob-
served as early as 6 h after addition of Zt/g4-DM1,
which features a significant reduction in G0/G1 phase, a
decrease in S phase, and a dramatic increase in G2/M
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phase. Quantitative measurement of cell cycle changes is
shown in Table 1. Clearly, Zt/g4-targeted delivery of
DM1 has a profound effect on cell cycle by BC and
NSCLC cells overexpressing RON.
We next studied the effect of Zt/g4-DM1 on viability
of BC and NSCLC cells using the MTT assay. CmIgG-
DM1 was used as the control. We first determined sen-
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Fig. 1 Binding and induction of RON internalization by Zt/g4-DM1. a Levels of RON expression by BC and NSCLC cell lines. Individual BC and
NSCLC cell lines (1 × 106 cells/ml) in 1 ml PBS in duplicates were incubated at 4 °C with 5 μg/ml of Zt/g4 for 60 min. Isotope matched mouse IgG
was used as the control. Cell surface RON was quantitatively determined by immuno-fluorescence analysis using QIFKIT® (DAKO). The number of
RON receptors was in a single cell was calculated according to the DAKO’s instruction. b Binding of DM1-conjugated Zt/g4 to cell surface RON.
Individual BC or NSCLC cell lines at (1 × 106 cells/ml) were incubated at 4 °C with 5 μg/ml of Zt/g4-DM1 for 60 min followed by flow cytometric
analysis. Control mouse IgG (CTL) and free Zt/g4 were used as the control. c The time-dependent RON internalization. BC and NSCLC cells
(1 × 106 cells per dish) were treated at 37 °C with 5 μg/ml of Zt/g4-DM1, collected at different time points, washed with acidic buffer to remove
Zt/g4 bound on the cell surface (31), and then incubated with 2 μg/mL of anti-RON mAb 2F2 [23]. Immunofluorescence was analyzed by flow
cytometer using FITC-coupled anti-mouse IgG. The FITC-binding intensity from cells treated with Zt/g4-DM1 at 4 °C was set as 100 %. The IE50
values were calculated as the time required to achieving 50 % reduction of cell surface RON. d and e Immunofluorescent analysis of cytoplasmic
RON: BC and NSCLC cells (1 × 105 cells per chamber) were treated at 4 °C or 37 °C with 5 μg/ml of Zt/g4-DM1 for 12 h followed by FITC-coupled
anti-mouse IgG. CmIgG-DM1 was used as the control. After cell fixation, immunofluorescence was detected using the BK70 Olympus microscope
equipped with a fluorescence apparatus. LAMP1 was used as a marker for protein cytoplasmic localization. DAPI was used to stain nuclear DNA
Feng et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:70 Page 4 of 14












Fig. 2 (See legend on next page.)
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IC50 values were 98.29 ± 2.89 nM for MCF-7; 12.42 ±
2.82 nM for DU4475; 23.45 ± 3.48 nM for MDA-MB-
231; 7.24 ± 1.45 nM for t-47D; 4.16 ± 0.38 nM for
H1993; 7.13 ± 0.51 nM for H358; and 6.59 ± 0.44 nM for
H2228, respectively. We then studied the effect of Zt/
g4-DM1 on cell viability. A significant reduction in cell
viability was observed in a dose-dependent manner in all
tested cell lines expressing high levels of RON (Fig. 2b).
The IC50 of Zt/g4-DM1 was 2.86 μg/ml for DU4475,
7.74 μg/ml for MDA-MB-231, 2.29 μg/ml for T- 47D,
5.13 μg/ml for H2228, and 2.44 μg/ml for H358 cells, re-
spectively. MCF-7 cells were not sensitive to Zt/g4-DM1.
Only a 12 % reduction in cell viability was observed after
cells were treated with 20 μg/ml of Zt/g4-DM1. Also,
H1993 cells expressing low levels of RON were only
slightly sensitive to Zt/g4-DM1. A 29 % reduction in cell
viability was documented after cells were treated with
15 μg/ml of Zt/g4-DM1. The kinetic effect of Zt/g4-DM1
on cell viability was studied using H2228 and H358
cells as the model (Fig. 2c). Zt/g4-DM1 caused a
time-dependent reduction in cell viability in both cell
lines tested. Thus, Zt/g4-DM1 is able to reduce cell
viability in both dose- and time-dependent manners
in cancer cells overexpressing RON.
Observation of cell morphology under a microscope in-
dicated a massive cell death after Zt/g4-DM1 treatment in
BC and NSCLC cells overexpressing RON with more than
50 % cell death after a 96 h treatment (Fig. 3a and b). The
calculated IC50 values were 2.02 ± 0.16 μg/ml for DU4475,
1.80 ± 0.10 μg/ml for MDA-MB-231, 6.12 ± 0.16 μg/ml
for T-47D, 1.78 ± 0.27 μg/ml for H358, and 1.96 ±
0.21 μg/ml for H2228 cells. Western blot analysis of
the PARP activation, a cellular apoptosis indicator
[38, 39] is shown in Fig. 3c. PARP fragments were
evident from BC and NSCLC cells in both time and
dose-dependent manners after Zt/g4-DM1 treatment.
Thus, Zt/g4-DM1 not only arrests cell cycles and de-
creases cell viability, but also reduces viable cell num-
bers and induces massive apoptotic cell death.
Correlations in vitro between the level of RON expression
and the efficacy of Zt/g4-DM1 on cell viability
A comparison between the efficacy of Zt/g4-DM1 (cell via-
bility IC50 value) and the number of RON receptors per
cell is shown in Fig. 4. The increased efficacy of Zt/g4-
DM1 as evident by decreased IC50 values is correlated with
the number of RON molecules expressed on the cell sur-
face. It appeared that the minimal number of cell-surface
RON molecules required for Zt/g4-DM1 to achieve a 95 %
reduction in cell viability (EC95) is around 10,000 mole-
cules per cell. A decrease in the level of RON receptors per
cell correlated proportionally with the diminished efficacy
of Zt/g4-DM1. Thus, cancer cells expressing ~10,000 RON
molecules on cell surface per cell appears to be required
for Zt/g4-DM1 in vitro to show the maximal activity.
Therapeutic activity of Zt/g4-directed DM1 delivery in
mouse xenograft tumor model
The goals of the in vivo study were to validate the effi-
cacy of Zt/g4-DM1 and to determine the tumoristatic
(See figure on previous page.)
Fig. 2 Effect of Zt/g4-DM1 on BC and NSCLC cell cycle, survival, and death. a Cell cycle changes: BC and NSCLC cell lines (1 × 106 cells per dish) were
treated at 37 °C with 5 μg/ml of Zt/g4-DM1 for various times, collected, stained with propidium iodide, and then analyzed by flow cytometer as previously
described [36]. MCF-7 cells were used as the control. Changes in cell cycle were marked with arrows. b Reduction of cell viability: BC and NSCLC cell lines
(5000 cells per well in a 96-well plate in triplicate) were treated with different amounts of Zt/g4-DM1 for 96 h. Cell viability was determined by the MTS
assay. The IC50 values were calculated using GraphPad Prism 6 software. c The kinetic effect of Zt/g4-DM1 on cell viability. H358 and H2228 cells were
cultured and treated with Zt/g4-DM1 as described in a. Cells were collected at 24, 48, 72, and 96 h followed by the MTT assay
Table 1 Effect of Zt/g4-Directed DM1 Delivery on Cell Cycle Changes by human breast and NSCLC Cell Linesa
Cancer cell lines Changes of cell cycles after Zt/g4-DM1 treatment (%)
G0/G1 phase S phase G2/M phase
0 h 6 h 12 h 24 h 0 h 6 h 12 h 24 h 0 h 6 h 12 h 24 h
MCF7 50.49 51.56 47.59 42.19 23.95 23.75 25.08 26.78 25.57 24.69 27.33 31.03
DU4475 51.14 40.92 23.22 10.13 10.42 18.24 16.37 13.5 38.42 40.91 60.40 76.37
MDA-MB-231 48.38 35.40 17.56 7.23 17.52 25.21 21.90 10.05 34.24 39.50 60.63 82.62
T-47D 64.71 62.81 35.63 14.74 7.06 10.15 28.61 10.29 28.24 27.04 35.76 74.97
H1993 56.40 54.55 53.28 50.17 16.00 16.53 18.03 15.87 27.60 28.93 28.69 33.95
H2228 63.56 58.23 48.85 27.21 13.98 13.92 12.95 8.16 22.46 27.85 38.20 64.63
H358 46.60 29.22 28.13 18.69 14.63 17.81 18.23 14.65 38.78 52.97 53.65 66.67
aBreast and NSCLC cell lines at 1 × 106 cells per culture dish in DMEM with 10 % FBS were treated at 37 °C for 0, 6, 12 and 24 h with 5 μg/ml of Zt/g4-DM1. After
treatment, cells were labeled with propidium iodide and then analyzed by an Accuri Flow Cytometer. Cell cycle changes were determined by measuring DNA
contents as previously described (25)
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Fig. 3 (See legend on next page.)
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concentration (TSC). The TSC is a dose that reaches a
balance in vivo between the tumor growth and inhib-
ition. To this end, mouse xenograft tumor models of
H1993, H288, H358, and T-47D cells were established.
Xenograft models for MDA-MB-231 and DU4475 cells
were unable to be established. Zt/g4-DM1 at 20 mg/kg
with a Q12 × 2 schedule was used for in vivo studies,
which was designed according to our previous studies
and the terminal half-life (t½: 6.01 days) of Zt/g4-DM1
(25). As shown in Fig. 5a, xenograft tumors initiated by
H1993 cells expressing only 2152 RON receptors per cell
were insensitive to Zt/g4-DM1. In contrast, Zt/g4- DM1
was highly effective in delaying tumor growth caused by
H2228, H358 and T-47D cell lines. The effect of Zt/g4-
DM1 in vivo was long lasting. At day 40, the tumor
growth inhibition was 96.12 % for H2228 and 95.66 %
for H358 cell xenograft tumors. For T-47D cell-initiated
tumors, Zt/g4-DM1 showed a tumor growth inhibition
at 86.4 % at day 36.
A comparison of tumor weight between the control
and Zt-g4-DM1 treated group at the end of experiments
was shown in Fig. 5b. In Zt/g4-DM1-treated H1993
xenograft tumors, we did not observe a statistical differ-
ence in tumor weight between the control and experi-
mental group, confirming that Zt/g4-DM1 has no effect
on tumors expressing low levels of RON. In contrast,
Zt/g4-DM1 was effective in inhibition of tumors ex-
pressing high levels of RON. Although tumors from Zt/
g4-DM1-treated H2228 and H358 cell groups were col-
lected 8 days later (day 44 for control mice versus day
52 for experimental animal), a significant reduction in
average tumor weight was still observed for H358
(82.58 %) and H2228 (90.71 %) cell-derived xenograft tu-
mors. Similarly, significant reduction in average tumor
weight (86.57 %) also was documented in T-47D cell de-
rived xenograft tumors. Thus, Zt/g4-DM1 at 20 mg/kg
in the Q12 × 2 regimen is effective in inhibition of xeno-
graft tumor growth initiated by H2228, H358 and T-
47D cells.
We calculated the TSCs based on the terminal half-life
of Zt/g4-DM1 in relationship with the tumor regrowth
curve (Fig. 5c). Zt/g4-DM1 in vivo has a terminal half-
life (t½) of 6.01 days [25]. The regrowth was found at
day 44 for both H2228 and H358, and day 36 for T-
47D- xenografts. The calculated TSCs were 2.02 mg/kg
for H2228, 1.94 mg/kg for H358, and 6.25 mg/kg for T-
47D cell-derived xenograft tumors, respectively. These
results indicate that in vivo Zt/g4-DM1 at ~2 mg/kg
is required to reach a tumoristatic status for H2228
and H358 cell-derived xenograft tumors. However, a
relatively high TSC at ~6.25 mg/kg is necessary to
balance the T-47D cell-derived tumor growth and
inhibition.
To exclude any possibilities that reduction of tumor is
related to general toxicity of Zt/g4- DM1 in vivo, we
monitored body weight of individual tumor-bearing mice
before and after treatment (Fig. 5d). All mice behaved
normally and their body weight progressively increased
during the entire observation period. Injection of cancer
cells did not alter mouse growth curve. Significantly, Zt/
g4-DM1 treatment did not halt mouse growth with in-
creased body weight. The average body weight of experi-
mental groups was comparable to that of control mice
with no statistical differences. Thus, results in Fig. 5d
(See figure on previous page.)
Fig. 3 Induction of cell apoptosis by Zt/g4-DM1. a morphological analysis of cell death. BC and NSCLC cells were treated with different amount of Zt/g4-
DM1 for 96 h. Morphological changes were observed under the Olympus BK-41 inverted microscope and photographed. Images showing cell death are
presented. b Dose-dependent cell death. BC and NSCLC cells were cultured and treated with Zt/g4-DM1 for 96 h as described in Fig. 1. The percentages
of cell death from individual cell lines were determined by the trypan blue exclusion assay. The IC50 values of cell death were calculated using the
GraphPad Prism 6 software. c PARK cleavage as cellular apoptosis. BC and NSCLC cells (2 × 106 cells in a 60 mm diameter dish) were treated with different
amounts of Zt/g4-DM1 as described in Fig. 1. Cells were collected at different intervals. Cellular proteins (50 μg per samples) were subjected to Western
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Fig. 4 The correlation between the efficacy of Zt/g4-DM1 and the
number of RON receptors expressed by cancer cells. The IC50 values for
cell viability and cell death were calculated using the GraphPad Prism
6 software and then plotted with individual BC and NSCLC cell lines
expressing different levels of RON. Colon cancer DLD-1 cells expressing
low levels of RON [25] also were included for comparison. The cell
surface RON numbers per cell are: DLD-1, 4480; MDA-MB-231, ~8185;
H228, 10,207; DU4475, 14,841; H358, 15,286; and T-47D, 15,756 RON
receptors per cell. The IC50 values at or less than 5 μg/ml of Zt/g4-DM1
were used as the effective dose to determine the RON receptor
number required to reach the IC95 value. Results shown here are from
one of three experiments with similar results
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Fig. 5 (See legend on next page.)
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demonstrate that tumor reduction is not related to the
general toxicity of Zt/g4-DM1 on mouse growth.
Therapeutic effect of Zt/g4-DM1 in combination with
chemotherapeutics
We first studied the activities of Zt/g4-DM1 in combin-
ation with chemotherapeutics. BC and NSCLC cell lines
were treated for 96 h in vitro with different amounts of
gemcitabine, Zt/g4-DM1 or their combinations at 1 to 1
molar ratio. Results in Fig. 6a show a progressive reduc-
tion of cell viability in both single and combination-
treated groups in all five cancer cell lines tested. Analysis
of data by plotting the fraction of inhibition against the
combination index (Fig. 6b) confirmed a synergism be-
tween Zt/g4-DM1 and gemcitabine at the defined con-
centrations in five cancer cell lines tested. An interesting
finding was in H2228 cells, in which a synergistic activity
was only observed when the low concentration of two
drugs were used (Fig. 6b).
We then performed the combination therapy in mouse
xenograft tumors, in which Zt/g4- DM1 at 10 mg/kg in
the Q8 × 2 regimen was combined with gemcitabine at
60 mg/kg in the Q4 × 4 schedule (Fig. 6c). Gemcitabine
alone partialy inhibited H358 and T-47D xenograft tu-
mors in a time-dependent manner with an average re-
duction in tumor volume at 51.3 and 73.8 % at day 36,
respectively. Similarly, Zt/g4-DM1 alone also partially
delayed the H358 and T-47D xenograft tumor growth at
day 36 with an average 68.0 and 71.1 % reduction in
tumor volume, respectively. The combination therapy
resulted in a significant inhibition of H358 and T-47D
xenograft tumors. An average growth inhibition in
tumor volume with statistical difference (p: <0.05) was
88.43 % for H358 and 90.62 % for T-47D. Measurement
of tumor weight at the end of the study further con-
firmed an increase in inhibition of tumor growth. For
H358 xenograft tumors, the average tumor weight from
the combined treatment groups (0.24 g ± 0.17) was sig-
nificantly less than that from the Zt/g4-DM1-treated
group (0.38 g ± 0.13, p <0.05) and from the gemcitabine-
treated group (0.50 g ± 0.14, p <0.05) (Fig. 6d). Similar
results also were observed in T-47D xenograft tumors,
in which the average tumor weight from the combin-
ation group (0.16 g ± 0.09) was much less than Zt-g4-
DM1 (0.59 g ±0.11) or gemcitabine (0.27 g ± 0.10)
treated groups (p <0.05). Thus, Zt/g4-DM1 in combin-
ation with gemcitabine results in the increase in inhib-
ition of T-47D and H358 xenograft tumors.
Discussion
The study presented here shows the effectiveness of Zt/
g4 in RON-targeted DM1 delivery for treatment of BC
and NSCLC. Both in vitro and in vivo studies demon-
strated the capability of Zt/g4 in induction of RON
internalization by cancer cells. Also, Zt/g4-directed de-
livery of DM1 is sufficient to cause cell cycle arrest in
G2/M phase, to inhibit cell proliferation and to cause
massive cell death. These functional analyses help to es-
tablish a correlation between the IC50 values for cell via-
bility and the levels of RON expression by cancer cells.
Studies from mouse xenograft tumor models confirmed
that Zt/g4 is suitable for DM1 delivery in vivo and Zt/
g4-DM1 at 20 mg/kg in the Q12 × 2 regimen inhibits
tumor growth with a long-lasting effect. The combin-
ational therapy further demonstrated that Zt/g4-DM1
together with chemoagents results further in delaying
BC and NSCLC xenograft tumor growth. Thus, Zt/g4-
DM1 is effective in the model of anti-RON ADC for
treatment of BC and NSCLC overexpressing the RON
receptor tyrosine kinase.
Selection of Zt/g4 for DM1 conjugation and delivery is
based on its unique feature in induction of RON intern-
alization [25, 34]. We noticed that the kinetics of Zt/
g4—induced RON internalization between BC and
NSCLC cell lines are quite different. The IE50 values for
BC cell lines expressing the high levels of RON (more
than 8000 RON molecules per cell) is in the range of
10 ~ 16 h. In contrast, the IE50 values for NSCLC
H2228 and H358 cell lines expressing similar levels of
RON were at the 7 to 10 h ranges. The mechanism(s)
underlying such differences currently is unknown. Regard-
less of the difference, Zt/g4-induced RON internalization
(See figure on previous page.)
Fig. 5 Therapeutic effect of Zt/g4-DM1 on BC and NSCLC cell-derived tumors. a Athymic nude mice (five mice per group) were subcutaneously
inoculated with 5 × 106 BC and NSCLC cells. Upon tumor volume reaching at ~100 mm3, Zt/g4-DM1 was injected through tail vein at 20 mg/kg
in a Q12 × 2 regimen. Control mice were injected with CmIgG-DM1. Tumor growth was monitored every 4 days by measuring tumor volume.
The percentages of inhibition were calculated by a formula: 1-(average tumor volume from Zt/g4-DM1 treated group)/(average tumor volume
from control mice) × 100 %. b Individual tumors from the control and experimental groups were collected and weighed at day 36, 44, or 52
dependent on individual tumor growth curves. The percentages of average tumor reduction were calculated by a formula: 1- (average tumor
weight from Zt/g4-DM1 treated group)/(average tumor weight from control mice) × 100 %. c The TSCs of Zt/g4-DM1 in vivo. The growth curve
of individual xenograft tumors from BC or NSCLC was analyzed with dynamics of Zt/g4-DM1 at 20 mg/kg in the Q12 × 2 regimen. Zt/g4-DM1 in
vivo has a terminal half-life (t½) of 6.01 days [25], which was plotted to the tumor regrowth curve. TSCs for H2228, H358, and T-47D cell
xenograft models were determined as the minimal dose of Zt/g4-DM1 required to balance the tumor growth and inhibition. d The effect of
Zt/g4-DM1 on mouse body weight. Control and tumor-bearing mice after Zt/g4-DM1 treatment as described in A were monitored every 4 days
for changes in their body weights. The percentages of changes in mouse body weight were calculated as previously described [25]
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Fig. 6 (See legend on next page.)
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is highly effective with more than 85 % of cell surface
RON internalized within 36 h. In the case of H358 cells
expressing ~15,000 RON molecules per cell, it translates
into 12,750 RON receptors that are internalized within
36 h. This is equivalent to 51,000 DM1 molecules deliv-
ered into a single cell, which is sufficient to cause cell
cycle arrest. In cell lines such as H1993 expressing the low
level of RON, Zt/g4 was able to induce RON internaliza-
tion with IE50 similar to those of other cancer cell lines
(Fig. 1b). However, the amount of internalized payload is
significantly less by calculation due to the low levels of the
RON expression. Considering the fact that normal epithe-
lial cells express low levels of RON, we reason that the
low density of RON in normal epithelial cells is not
enough to bring sufficient amount of DM1 to cause
significant biological activity. Results in Fig. 2 appear to
support this notion. Thus, Zt/g4-induced RON internal-
ization facilitates intracellular delivery of DM1 in cancer
cells expressing high levels of RON.
The action of DM1 delivered by Zt/g4 was displayed
in both BC and NSCLC cells. First, we showed by flow
cytometric analysis that the Zt/g4-DM1 internalization
causes cell cycle arrest in G2/M phase, which is a feature
of DM1 that impairs microtubule dynamics [40]. This ef-
fect was observed as early as 6 h after the addition of
Zt/g4-DM1 and characterized by progressive reduction
of the G1 phase and the accumulation of cells at the G2/
M phase. Second, we found that Zt/g4-directed DM1 de-
livery progressively decreases cell viability. More than
80 % reduction in cell viability 96 h after treatment was
achieved among three BC and two NSCLC cell lines
tested. Third, we documented a massive cell death in Zt/
g4-DM1-treated BC and NSCLC cells in a dose-
dependent manner with Zt/g4-DM1 IC50 values ranging
from 2 to 6 μg/ml. Analysis of cellular markers for apop-
totic death further confirmed that Zt/g4-DM1 treatment
activates PARP as evident by the presence of the PARP
fragment. These findings indicate that DM1-mediated
cell cycle arrest leads to initiation of an intracellular
apoptotic pathway. Finally, we discovered that the effi-
cacy of Zt/g4-DM1 in vitro directly correlates with the
levels of the RON expression by cancer cells. For Zt/g4-
DM1 to achieve a significant reduction in cell viability,
the minimal RON molecule expressed by cancer cells
should be at ~8000 receptors per cells. We reason that
such a correlational relationship is useful for predicting
the in vitro effectiveness of Zt/g4-DM1 against cancer
cells, which helps to select potential target cancer cells
for evaluation in vivo.
Results from mouse xenograft tumor models demon-
strate the efficacy of Zt/g4-DM1 in inhibition of tumor
growth. It is possible that Zt/g4-mediated immunological
activities may also contribute the observed therapeutic ef-
ficacy. As described in other ADCs, antibody-dependent
cell-mediated cytotoxicity, antibody dependent cellular
phagocytosis, and complement- dependent cytotoxicity
play a role in vivo in the ADC anticancer activity [13]. We
used Zt/g4- DM1 at 20 mg/kg in the Q12 × 2 regimen for
the animal study. This dosing regimen was designed to de-
termine whether Zt/g4-DM1 at a total of 40 mg/kg in a
particular period is sufficient to inhibit tumor growth. We
showed that the action of Zt/g4-DM1 is dependent on
levels of the RON expression. Zt/g4-DM1 effectively
inhibited xenograft tumor growth mediated by H228,
H358, and T-47D cells but has no effect on H1993 cell-
mediated tumors. By applying pharmacokinetic data of
Zt/g4-DM1, we monitored Zt/g4-DM1 efficacy for several
half-life cycles, which confirms that Zt/g4-DM1 has the
long-lasting effect of up to 2 weeks without signs of tumor
regrowth (from day 24 to day 40 in the NSCLC model
and from day 24 to day 36 in the BC model) (Fig. 5a).
Moreover, we established the TSC as the indicator of
Zt/g4-DM1 for monitoring xenograft tumor growth,
which should help us to predict the dose-response
curve and to design the treatment regimen for further
study [41, 42]. Finally, we observed that the Zt/g4-
DM1 regimen used in vivo did not exert significant
toxicity towards animals. An increase in the average
body weight was observed in Zt/g4-DM1 treated ani-
mals. Considering these facts, we conclude that Zt/
g4-DM1 is effective and safe in the targeted treatment
of BC and NSCLC xenograft tumors.
(See figure on previous page.)
Fig. 6 Synergism between Zt/g4-DM1 and chemotherapeutics. a the synergistic effect of Zt/g4-DM1 and gemcitabine in vitro. BC and NSCLC cell
lines (8000 cell per well in a 96-well plate in triplicate) were cultured in DMEM with 10 % FBS and treated for 96 h with different amounts of
gemcitabine, Zt/g4-DM1, or their combinations at 1:1 molar ratio. Cell viability was measured using the MTT assay. b Analysis of the synergism by
Chou-Talalay plot. Percentages of cell viability from individual samples as described in A were calculated, converted, and then used for the frac-
tion of inhibition-combination index (CI) plot as previously described [43]. Data shown here are from one of three experiments with similar results.
c Effect of Zt/g4-DM1 in combination with gemcitabine in vivo. Athymic nude mice (five mice per group) were subcutaneously inoculated with
5 × 106 H358 or T-47D cells to allow tumor growth to reach an average volume at ~100 mm3. Zt/g4-DM1 at 10 mg/kg in a
Q8 × 3 regimen was injected through tail vein. Mice injected with CmIgG-DM1 were used as the control. Gemcitabine was injected into the
intraperitoneal cavity at 60 mg/kg in a Q4 × 4 schedule. Both drugs were used for the combination group according to their own dose and
schedule. Tumor volume was measured every 4 days. The percentages of tumor growth inhibition were calculated from the average tumor
volume as described in Fig. 5a. d Tumor inhibition by measuring tumor weight. Individual tumors from different groups were collected and weighed
to obtain the average tumor weight (gram). The percentages of reduction in average tumor weight were calculated as described in Fig. 5b
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Studies using H358 and T-47D xenograft models dem-
onstrated the increase in therapeutic activity between
Zt/g4-DM1 and gemcitabine in inhibition of tumor
growth. We showed from in vitro studies that the com-
bination of Zt/g4-DM1 with chemotherapeutics at the
same molar ratio further reduce viability of BC and
NSCLC cells. Analysis of the average tumor weight at
the end of the study also confirmed the increase in
therapeutic activity between Zt/g4-DM1 and chemother-
apeutics. This indicates that the inhibition can be syner-
gized through different mechanisms of action. It is
worth to note that the synergism of Zt/g4-DM1 with
gemcitabine is dependent on individual cancer cell lines
in the particular dose range. We reasoned from the
combination therapy that since BC and NSCLC tumors
are highly malignant at the later stage, Zt/g4-DM1 in
combination with chemotherapeutics could be a strategy
for targeted cancer therapy.
Conclusions
We present evidence in this study that anti-RON antibody
directed delivery of the highly potent drug DM1 in the
form of ADC is a therapeutic strategy for targeted treat-
ment of breast and NSCLC cancer in animal models. Re-
sults from various in vitro and in vivo experiments
showed that Zt/g4-DM1 not only significantly decreases
viability of breast cancer and NSCLC cells but also dra-
matically delays the tumor growth in mouse xenograft
tumor models. Moreover, we demonstrated that Zt/g4-
DM1 in combination gemcitabine significantly increases
the inhibitory effect on xenograft tumor growth. These
findings lay the foundation for clinical development of
anti-RON ADC Zt/g4-DM1 for potential cancer therapy.
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